Zalzal Habib, Pershad Alisha, Behzadpour Hengameh, Rana Md Sohel, Zalzal George
Department of Otolaryngology, Children's National Hospital, Washington, DC.
School of Medicine & Health Sciences, George Washington University, Washington, DC.
JAMA Otolaryngol Head Neck Surg. 2025 May 29. doi: 10.1001/jamaoto.2025.1201.
Acid suppression therapy is frequently administered to infants with laryngomalacia presenting with stridor despite limited evidence in the literature reporting its efficacy for this subset of patients.
To evaluate the frequency of supraglottoplasty in infants with nonsevere laryngomalacia treated with gastroesophageal reflux disease (GERD) medications.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included infants younger than 6 months with a clinical diagnosis of nonsevere laryngomalacia initially managed with either watchful waiting or GERD medications. Patients were recruited from 2014 to 2023 to a pediatric otolaryngology airway clinic at a tertiary care pediatric hospital.
The primary outcome was the frequency of supraglottoplasty following nonsurgical management. Patients with nonsevere laryngomalacia were divided into 2 groups based on whether their laryngomalacia was managed with GERD medication therapy or observation alone. The aim was to assess the difference in supraglottoplasty rates between these 2 groups.
The medical records of 395 infants younger than 6 months (171 female, 224 male) with nonsevere laryngomalacia managed with observation after their initial otolaryngology evaluation were analyzed: observation (n = 320) and trial of GERD medications (n = 75). Baseline characteristics between the observation and GERD medication groups were similar. The overall supraglottoplasty rate was 4.1% (16/395), with a small increase in the use of surgical treatment between the observation and GERD medication cohorts (3.4% vs 6.7%; difference, -3.2% [95% CI, -10% to 3.6%]). The imprecision in the estimate prevents making a definitive conclusion regarding the observed difference.
This study found that rates of supraglottoplasty in infants with nonsevere laryngomalacia with GERD managed with GERD medications were similar to those without reflux managed with watchful waiting. Female sex and severity of laryngomalacia based on endoscopic examination were the best predictors of receipt of supraglottoplasty after a period of watchful waiting.
尽管文献中关于酸抑制疗法对患有喘鸣的喉软化症婴儿疗效的证据有限,但仍经常对这类婴儿使用该疗法。
评估接受胃食管反流病(GERD)药物治疗的非重度喉软化症婴儿行声门上成形术的频率。
设计、背景和参与者:这项回顾性队列研究纳入了6个月以下临床诊断为非重度喉软化症且最初采用观察等待或GERD药物治疗的婴儿。研究对象于2014年至2023年被招募至一家三级儿科医院的儿科耳鼻喉科气道门诊。
主要结局是在非手术治疗后行声门上成形术的频率。非重度喉软化症患者根据其喉软化症是采用GERD药物治疗还是仅观察分为两组。目的是评估这两组之间声门上成形术率的差异。
分析了395例6个月以下非重度喉软化症婴儿(171例女性,224例男性)的病历,这些婴儿在初次耳鼻喉科评估后采用观察等待:观察(n = 320)和GERD药物试验(n = 75)。观察组和GERD药物组的基线特征相似。总体声门上成形术率为4.1%(16/395),观察队列和GERD药物队列之间手术治疗的使用略有增加(3.4%对6.7%;差异,-3.2%[95%CI,-10%至3.6%])。估计的不精确性使得无法就观察到的差异得出明确结论。
本研究发现,采用GERD药物治疗GERD的非重度喉软化症婴儿的声门上成形术率与采用观察等待治疗无反流的婴儿相似。女性性别和基于内镜检查的喉软化症严重程度是观察等待一段时间后接受声门上成形术的最佳预测因素。